Rocket Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Highlights Recent Progress
Rocket Pharmaceuticals, Inc. (RCKT)
Last rocket pharmaceuticals, inc. earnings: 3/5 07:00 am
Check Earnings Report
US:NASDAQ Investor Relations:
rocketpharma.com
Company Research
Source: Business Wire
Pivotal Phase 2 trial of RP-A501 for Danon disease to resume in 1H 2026KRESLADI™ for severe LAD-I on track for March 28, 2026 PDUFA dateDosing of first patient in Phase 1 study of RP-A701 for BAG3-related dilated cardiomyopathy anticipated in mid-2026Cash, cash equivalents and investments of approximately $188.9M; expected operational runway into the second quarter of 2027 CRANBURY, N.J.--(BUSINESS WIRE)--Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT), a fully integrated, late-stage biotechnology company advancing a sustainable pipeline of genetic therapies for rare disorders with high unmet need, today reported financial and recent operational results for the fourth quarter and year ended December 31, 2025.“In 2025, we strengthened Rocket’s leadership in cardiovascular gene therapy, supported by more than five years of clinical experience in Danon disease and continued advancement across our PKP2-ACM and BAG3-DCM programs,” said Gaurav Shah, M.D., Chief Executive Officer of Rocket Ph
Show less
Read more
Impact Snapshot
Event Time:
RCKT
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
RCKT alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
RCKT alerts
High impacting Rocket Pharmaceuticals, Inc. news events
Weekly update
A roundup of the hottest topics
RCKT
News
- Wedbush sees Rocket Pharmaceuticals as significantly undervalued as cardiac gene therapy pipeline advances [Yahoo! Finance]Yahoo! Finance
- Rocket Pharmaceuticals (RCKT) had its price target raised by The Goldman Sachs Group, Inc. from $2.00 to $3.00. They now have a "sell" rating on the stock.MarketBeat
- Rocket Pharmaceuticals (RCKT) was upgraded by Lifesci Capital to "strong-buy".MarketBeat
- RCKT's Q4 Loss Narrower Than Estimated, Pipeline in Focus [Yahoo! Finance]Yahoo! Finance
- Rocket Pharmaceuticals (RCKT) had its price target raised by Cantor Fitzgerald from $8.00 to $10.00. They now have an "overweight" rating on the stock.MarketBeat
RCKT
Earnings
- 2/26/26 - Beat
RCKT
Sec Filings
- 3/2/26 - Form S-3
- 2/26/26 - Form 8-K
- 2/26/26 - Form 10-K
- RCKT's page on the SEC website